Characteristics and Treatment Experiences of Individuals Using Injectable Semaglutide for Weight Management, a Cross-sectional Time-series Analysis, Multi-country Study.

Inclusion Criteria

• •1. Electronically provided consent obtained before any study-related activities can be completed.
• •2. Age above or equal to 18 years at the time of providing informed consent.
• •3. Reside in a participating country: Australia, Germany, United Arab Emirates (UAE) and Spain.
• •4. Have been prescribed and initiated injectable semaglutide for weight management prior to study screening.
• •1. Electronically provided consent obtained before any study-related activities can be completed.
• •2. Practice in a participating country: Australia, Germany, UAE, and Spain.
• •3. See at least 150 patients for any condition per month; priority given to those who treat at least 200 patients for any condition per month.
• •4. Treat at least 10 adult patients per month for weight management.
• •5. Prescribe anti-obesity medications (AOMs) to their patients they personally treat for weight management/obesity care; priority given to those who treat at least 10% of the patients they personally treat for weight management/obesity care with anti-obesity medications (AOMs).
• •6. Prescribe injectable semaglutide for weight management.
• •7. Be a specialty of interest (varies by country); mix of primary care, specialists such as Endocrinologists, Diabetologists, Nutrition Specialists, Obesity Specialists and others.